Nkarta (NKTX) stock jumps after the FDA agrees to outpatient dosing of NKX019 in lupus nephritis trials, cutting the patient monitoring to 2 hours. Read more here.
Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ)
Nkarta (NKTX) stock jumps after the FDA agrees to outpatient dosing of NKX019 in lupus nephritis trials, cutting the patient monitoring to 2 hours. Read more here.